Clinical Presentations of Parvovirus B19: A Case Series.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
Parvovirus B19 (PVB19) is a small, nonenveloped, single-stranded DNA virus commonly causing asymptomatic infections or mild, flu-like symptoms. In children, PVB19 can lead to various clinical conditions, including erythema infectiosum, arthropathy, transient aplastic crisis and papular-purpuric eruptions, among others. We present 3 pediatric cases treated at Luigi Sacco University Hospital in Milan, Italy, in March 2024, each demonstrating distinct manifestations of PVB19 infection. Case 1 involved a 7-year-old girl with a maculopapular rash and panniculitis-like symptoms. Case 2 described an 8-year-old boy with a maculopapular rash, vasculitis component and mild thrombocytopenia. Case 3 focused on a 7-year-old girl with petechial and purpuric eruptions and a mild decrease in platelets. Serological tests confirmed PVB19 infection in all cases. The discussed cases highlight the heterogeneous clinical spectrum of PVB19 infection and emphasize its potential to cause thrombocytopenia even in healthy children. The recent surge in PVB19 cases in Europe, aligned with known epidemiological cycles, underscores the importance of vigilance in diagnosis, particularly during peak seasons. Additionally, concerning the role of serological testing in the diagnostic process, the potential for cross-reactivity among viral antigens is pointed out. PVB19 is a common infection with a broad range of clinical presentations. Awareness of its potential complications, including thrombocytopenia, even in nonimmunocompromised children, is crucial. Moreover, understanding the epidemiological patterns of PVB19 can aid in anticipating and managing outbreaks, thus minimizing its impact on pediatric health.
Sections du résumé
BACKGROUND
BACKGROUND
Parvovirus B19 (PVB19) is a small, nonenveloped, single-stranded DNA virus commonly causing asymptomatic infections or mild, flu-like symptoms. In children, PVB19 can lead to various clinical conditions, including erythema infectiosum, arthropathy, transient aplastic crisis and papular-purpuric eruptions, among others.
METHODS
METHODS
We present 3 pediatric cases treated at Luigi Sacco University Hospital in Milan, Italy, in March 2024, each demonstrating distinct manifestations of PVB19 infection. Case 1 involved a 7-year-old girl with a maculopapular rash and panniculitis-like symptoms. Case 2 described an 8-year-old boy with a maculopapular rash, vasculitis component and mild thrombocytopenia. Case 3 focused on a 7-year-old girl with petechial and purpuric eruptions and a mild decrease in platelets. Serological tests confirmed PVB19 infection in all cases.
RESULTS
RESULTS
The discussed cases highlight the heterogeneous clinical spectrum of PVB19 infection and emphasize its potential to cause thrombocytopenia even in healthy children. The recent surge in PVB19 cases in Europe, aligned with known epidemiological cycles, underscores the importance of vigilance in diagnosis, particularly during peak seasons. Additionally, concerning the role of serological testing in the diagnostic process, the potential for cross-reactivity among viral antigens is pointed out.
CONCLUSION
CONCLUSIONS
PVB19 is a common infection with a broad range of clinical presentations. Awareness of its potential complications, including thrombocytopenia, even in nonimmunocompromised children, is crucial. Moreover, understanding the epidemiological patterns of PVB19 can aid in anticipating and managing outbreaks, thus minimizing its impact on pediatric health.
Identifiants
pubmed: 39230325
doi: 10.1097/INF.0000000000004541
pii: 00006454-990000000-00996
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Qiu J, Söderlund-Venermo M, Young NS. Human parvoviruses. Clin Microbiol Rev. 2017;30:43–113.
Kerr JR. Parvovirus B19 infection. Eur J Clin Microbiol Infect Dis. 1996;15:10–29.
Reno ML, Cox CR, Powell EA. Parvovirus B19: a clinical and diagnostic review. Clin Microbiol Newsl. 2022;44:107–114.
Katta R. Parvovirus B19: a review. Dermatol Clin. 2002;20:333–342.
Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007;75:373–376.
Smith PT, Landry ML, Carey H, et al. Papular-purpuric gloves and socks syndrome associated with acute parvovirus B19 infection: case report and review. Clin Infect Dis. 1998;27:164–168.
Feldmann R, Harms M, Saurat JH. Papular-purpuric “gloves and socks” syndrome: not only parvovirus B19. Dermatology. 1994;188:85–87.
Fretzayas A, Douros K, Moustaki M, et al. Papular-purpuric gloves and socks syndrome in children and adolescents. Pediatr Infect Dis J. 2009;28:250–252.
Diseases ACOI. Red Book (2018): Report of the Committee on Infectious Diseases. 31st ed. In Kimberlin DW, Brady MT, Jackson MA, eds. American Academy of Pediatrics; 2018.
European Centre for Disease Prevention and Control (ECDC). Communicable Disease Threats Report - 14 -20 April 2024, Week 16. ECDC; 2024.
Italian Ministry of Health. Surveillance data on Parvovirus B19 infections. Retrieved from Salute.gov.it. Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA – 5 June 2024. 2024.
Furkan Demir B, Karahan Meteris A, Yirgin G, et al. Parvovirus-induced thrombocytopenia. Hematol Oncol Stem Cell Ther. 2019;12:226–227.
Murray JC, Kelley PK, Hogrefe WR, et al. Childhood idiopathic thrombocytopenic purpura: association with human parvovirus B19 infection. Am J Pediatr Hematol Oncol. 1994;16:314–319.
Aktepe OC, Yetgin S, Olcay L, et al. Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 2004;21:421–426.
Thomas HI, Barrett E, Hesketh LM, et al. Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infection. J Clin Virol. 1999;14:107–118.
Donovan SM. False-positive results of an enzyme immunoassay for rubella IgM in a case of measles. Clin Infect Dis. 1997;24:271–272.
Jensen IP, Vestergaard BF. Assessment of the specificity of a commercial human parvovirus B19 IgM assay. Clin Diagn Virol. 1997;7:133–137.